SAR422459
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt's Disease
Conditions
Stargardt's Disease
Trial Timeline
Jun 8, 2011 → Aug 16, 2019
NCT ID
NCT01367444About SAR422459
SAR422459 is a phase 1/2 stage product being developed by Sanofi for Stargardt's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01367444. Target conditions include Stargardt's Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01367444 | Phase 1/2 | Terminated |
Competing Products
6 competing products in Stargardt's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| avacincaptad pegol + Sham | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| hESC-RPE | Astellas Pharma | Pre-clinical | 23 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Sanofi | Phase 2 | 51 |